Published in Nature on August 02, 2012
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 11.93
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet (2013) 3.51
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet (2014) 3.17
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature (2014) 2.81
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov (2014) 2.64
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell (2014) 2.57
Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med (2013) 2.55
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet (2013) 2.21
Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell (2016) 2.12
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell (2016) 2.04
Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res (2014) 1.86
Consistent in-frame internal tandem duplications of BCOR characterize clear cell sarcoma of the kidney. Nat Genet (2015) 1.84
The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83
H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. Elife (2013) 1.81
Divergent clonal selection dominates medulloblastoma at recurrence. Nature (2016) 1.81
Tracing the cellular origin of cancer. Nat Cell Biol (2013) 1.75
Neuroblastoma and MYCN. Cold Spring Harb Perspect Med (2013) 1.75
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol (2015) 1.72
Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res (2013) 1.70
Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov (2014) 1.63
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev (2013) 1.62
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Cancer genome-sequencing study design. Nat Rev Genet (2013) 1.55
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet (2013) 1.53
BAF complexes facilitate decatenation of DNA by topoisomerase IIα. Nature (2013) 1.52
Existing and emerging technologies for tumor genomic profiling. J Clin Oncol (2013) 1.52
Targeting EZH2 in cancer. Nat Med (2016) 1.51
Non-canonical Hedgehog/AMPK-Mediated Control of Polyamine Metabolism Supports Neuronal and Medulloblastoma Cell Growth. Dev Cell (2015) 1.49
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med (2014) 1.38
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Sci Adv (2015) 1.33
Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol (2012) 1.33
DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol (2013) 1.27
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma. Nat Genet (2015) 1.23
Chromatin signatures of cancer. Genes Dev (2015) 1.20
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res (2013) 1.20
Exomic sequencing of four rare central nervous system tumor types. Oncotarget (2013) 1.17
Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet (2016) 1.15
Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol (2014) 1.15
Children's Oncology Group's 2013 blueprint for research: central nervous system tumors. Pediatr Blood Cancer (2012) 1.14
Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc Natl Acad Sci U S A (2012) 1.14
TET proteins and the control of cytosine demethylation in cancer. Genome Med (2015) 1.13
Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. Nat Commun (2014) 1.12
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol (2016) 1.11
Structure of the polycomb group protein PCGF1 in complex with BCOR reveals basis for binding selectivity of PCGF homologs. Structure (2013) 1.11
The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants. Oncogene (2014) 1.11
Role of MYC in Medulloblastoma. Cold Spring Harb Perspect Med (2013) 1.10
NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. Database (Oxford) (2014) 1.10
DICER1-pleuropulmonary blastoma familial tumor predisposition syndrome: a unique constellation of neoplastic conditions. Pathol Case Rev (2014) 1.09
Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney. Nat Commun (2015) 1.09
The prenatal origins of cancer. Nat Rev Cancer (2014) 1.09
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet (2016) 1.07
Histone H3 lysine 4 methyltransferases and demethylases in self-renewal and differentiation of stem cells. Cell Biosci (2013) 1.07
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget (2013) 1.06
SWI/SNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet (2014) 1.03
Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. J Clin Oncol (2015) 1.02
Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat Commun (2014) 1.00
Targeting DDX3 with a small molecule inhibitor for lung cancer therapy. EMBO Mol Med (2015) 1.00
Biochemical reconstitution and phylogenetic comparison of human SET1 family core complexes involved in histone methylation. J Biol Chem (2015) 0.99
The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. Am J Pathol (2015) 0.99
Cellular potts modeling of tumor growth, tumor invasion, and tumor evolution. Front Oncol (2013) 0.99
Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell (2014) 0.98
Personal genomes, quantitative dynamic omics and personalized medicine. Quant Biol (2013) 0.98
Driver mutations of cancer epigenomes. Protein Cell (2014) 0.98
The H3K27me3 demethylase UTX in normal development and disease. Epigenetics (2014) 0.97
Protein domain-level landscape of cancer-type-specific somatic mutations. PLoS Comput Biol (2015) 0.97
Epigenomic regulation of oncogenesis by chromatin remodeling. Oncogene (2016) 0.97
Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer. Pharmacol Rev (2014) 0.96
Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res (2014) 0.96
DNA replication error-induced extinction of diploid yeast. Genetics (2014) 0.95
Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. Oncotarget (2014) 0.95
The rationale for targeted therapies in medulloblastoma. Neuro Oncol (2013) 0.92
Casein kinase 1δ is an APC/C(Cdh1) substrate that regulates cerebellar granule cell neurogenesis. Cell Rep (2015) 0.92
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol Commun (2015) 0.91
A precise chloroplast genome of Nelumbo nucifera (Nelumbonaceae) evaluated with Sanger, Illumina MiSeq, and PacBio RS II sequencing platforms: insight into the plastid evolution of basal eudicots. BMC Plant Biol (2014) 0.91
The Brm-HDAC3-Erm repressor complex suppresses dedifferentiation in Drosophila type II neuroblast lineages. Elife (2014) 0.90
Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. Epigenetics (2013) 0.89
Targeted or whole genome sequencing of formalin fixed tissue samples: potential applications in cancer genomics. Oncotarget (2015) 0.89
Chromatin-regulating proteins as targets for cancer therapy. J Radiat Res (2014) 0.88
Examining the impact of gene variants on histone lysine methylation. Biochim Biophys Acta (2014) 0.88
Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer. Oncotarget (2015) 0.88
Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. Br J Haematol (2014) 0.87
Drosophila SETs its sights on cancer: Trr/MLL3/4 COMPASS-like complexes in development and disease. Mol Cell Biol (2013) 0.87
An epigenetic switch induced by Shh signalling regulates gene activation during development and medulloblastoma growth. Nat Commun (2014) 0.87
Deep sequencing identifies IDH1 R132S mutation in adult medulloblastoma. J Clin Oncol (2014) 0.87
Mutation of cancer driver MLL2 results in transcription stress and genome instability. Genes Dev (2016) 0.86
Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors. F1000Prime Rep (2014) 0.86
Robust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples. Sci Rep (2015) 0.86
Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma. Childs Nerv Syst (2013) 0.85
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Accurate whole human genome sequencing using reversible terminator chemistry. Nature (2008) 90.20
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer (2011) 6.87
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Structural basis for RNA unwinding by the DEAD-box protein Drosophila Vasa. Cell (2006) 5.70
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell (2011) 4.70
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
DOG 1.0: illustrator of protein domain structures. Cell Res (2009) 2.77
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71
Adult medulloblastoma comprises three major molecular variants. J Clin Oncol (2011) 2.07
Mutations in PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with holoprosencephaly. Hum Genet (2002) 1.80
Regulated subset of G1 growth-control genes in response to derepression by the Wnt pathway. Proc Natl Acad Sci U S A (2003) 1.68
Crystal structure of conserved domains 1 and 2 of the human DEAD-box helicase DDX3X in complex with the mononucleotide AMP. J Mol Biol (2007) 1.58
Structural basis for the assembly of the SMRT/NCoR core transcriptional repression machinery. Nat Struct Mol Biol (2011) 1.53
Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs). Cancer (2011) 1.39
Dullard promotes degradation and dephosphorylation of BMP receptors and is required for neural induction. Dev Cell (2006) 1.32
The RNA helicase database. Nucleic Acids Res (2010) 1.15
A motif unique to the human DEAD-box protein DDX3 is important for nucleic acid binding, ATP hydrolysis, RNA/DNA unwinding and HIV-1 replication. PLoS One (2011) 1.13
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature (2007) 65.18
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
Integrating common and rare genetic variation in diverse human populations. Nature (2010) 32.30
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature (2008) 30.29
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
GenePattern 2.0. Nat Genet (2006) 29.07
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Efficiency and power in genetic association studies. Nat Genet (2005) 25.56
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
ARACHNE: a whole-genome shotgun assembler. Genome Res (2002) 22.72
Detecting recent positive selection in the human genome from haplotype structure. Nature (2002) 22.00
Signatures of mutational processes in human cancer. Nature (2013) 21.63
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet (2008) 19.55
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med (2007) 17.06
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48